advertisement

HIV/AIDS

20 April 2011

HIV/Aids: Prevention drug trial disappoints

A three-country study has been halted after daily doses of the ARV Truvada, used as a pre-exposure prophylaxis, failed to prevent HIV infection in the women participating.

A three-country study has been halted after daily doses of the antiretroviral (ARV) Truvada, used as a pre-exposure prophylaxis (PrEP), failed to prevent HIV infection in the women participating.

Results surprizing, disappointing

The results were both surprising and disappointing after several PrEP success stories, but researchers would start analysing the data and blood samples to pinpoint why the drug did not work, said Dr Timothy Mastro, FHI Vice President of Health and Development.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.